Komori
Governance4884Kringle Pharma,Inc.Pharmaceuticals

Notice Concerning the Introduction of an Executive Officer System

Effective 1 October 2026, the company will establish an executive officer system and change to a structure under which the Board of Directors decides on the appointment and dismissal of executive officers. Five people, including 4 directors, will serve as executive officers, with Adachi Kiichi (安達喜一) serving as CEO.

Worth reading
61In focus
Scored from 1 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
5
Executive officers (including 4 directors)
Wording
Definitive
How definitive the wording is.

Contents of this filing

Changes this time

Effective 1 October 2026, the company will introduce an executive officer system, with Adachi Kiichi (安達喜一) serving as CEO. Murakami Koichi (村上浩一), Hayata Taishin (早田大真) and Kayano Yoshiyuki (茅野善行) will serve as both directors and executive officers, and Kinjo Kazutaka (金城一貴) will be appointed as an executive officer.

この書類は、機関設計や取締役会の構成そのものは述べていません。上に示したのは、この書類が述べている変更点です。

Contents of this filing
ItemDetails
Changes this timeEffective 1 October 2026, the company will introduce an executive officer system, with Adachi Kiichi (安達喜一) serving as CEO. Murakami Koichi (村上浩一), Hayata Taishin (早田大真) and Kayano Yoshiyuki (茅野善行) will serve as both directors and executive officers, and Kinjo Kazutaka (金城一貴) will be appointed as an executive officer.
Items this document does not state (7)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In anticipation of intensifying preparations for commercialization as development progresses and expanding overseas operations, the company aims to clarify responsibilities and authority across specialized functions, including research and development, manufacturing and business development, and establish a more rapid and flexible operating structure. Through this, it aims to strengthen its management foundation and sustainably enhance corporate value.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Introduction of an Executive Officer System | Kringle Pharma,Inc. (4884) timely disclosure | Komori